BioSpace News Archive

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of a groundbreaking study at the 2023 World Conference on Lung Cancer (WCLC 2023), to be held in Singapore on September 9-12.

Expanse Medical, the innovative medical device incubator founded by Eitan Konstantino with focus on global innovations, proudly announces the addition of Shlomi Nachman to its Board of Directors and the Board of its spinoff, Expanse ICE.

Harvard Apparatus Regenerative Technology, Inc. today announced the Approval of an Orphan Disease Application for its lead product, the Cellspan Esophageal Implant by the European Medicines Agency (EMA).

Sentient, the leading full-service provider to the aesthetic care industry, announced today that the U.S. Food and Drug Administration has approved Tixel by Sentient, its innovative non-invasive skin resurfacing technology, for the treatment of periorbital wrinkles.

Scale Biosciences today announced a new collaboration with Basepair to provide point and click bioinformatic analysis of single-cell data produced with its patented and disruptive combinatorial indexing technology.

Mammotome announced the launch of an innovative new HydroMARK™ Plus Breast Biopsy Site Marker designed to enhance ultrasound visibility, improve ease of locating, and mitigate displacement during surgical procedures.

Suono Bio, the company reimagining targeted drug delivery of novel medicines through ultrasound-mediated delivery, has secured an exclusive option agreement with the Massachusetts Institute of Technology (MIT) covering the first-in-kind “RoboCap” oral pill intellectual property.

In a recently published study conducted at Skåne University Hospital, Prostatype® shows significantly better results in predicting death from prostate cancer within 10 years compared to both D’Amico and CAPRA, today’s leading classification system for prostate cancer.

GordonMD® Global Investments LP announced today it has participated in a $150 million private placement financing for Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS).

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2023 interim results.